82 filings
Page 2 of 5
8-K
g275wo
21 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
oflgwjm
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
fx1kllukho5hbht fe
23 Jan 24
Departure of Directors or Certain Officers
4:01pm
8-K
kpuo0 ajyn
21 Dec 23
Regulation FD Disclosure
9:15am
8-K
hp27m47xxcd3c
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
8-K
c1ocy03o6e z0z5k
15 Nov 23
Results of Operations and Financial Condition
8:00am
8-K
a5329m ho1plntls8c
18 Oct 23
Regulation FD Disclosure
9:00am
8-K
5brqqi
17 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
mjcnunmk
18 Sep 23
Submission of Matters to a Vote of Security Holders
7:51pm
8-K
lwhpasqw
18 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
dh28 qrjs0
15 Aug 23
Amendments to Articles of Incorporation or Bylaws
8:30am
8-K
naft8v5mvpsc
14 Aug 23
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Continued rapid pace of enrollment with ~75% of expected patients now enrolled
9:25am
8-K
zomy5lq7qpqunl1gjb6
15 May 23
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides
8:36am
8-K
gvx7i feg
8 May 23
Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
8:45am
8-K
2gggzfq7zzrw41
3 Jan 23
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
8:45am
8-K
ey1yai nsli7tl9tr7ee
14 Dec 22
Other Events
4:00pm
8-K
cl6lmhcf
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm
8-K
9sdsg gt76ehy
28 Nov 22
CNS Pharmaceuticals Announces Reverse Stock Split
5:13pm
8-K
xfa w08a0ayqf4zt
24 Oct 22
Other Events
5:15pm
8-K
7rkfzgs27t0dlk09odb
26 Aug 22
Submission of Matters to a Vote of Security Holders
5:00pm